Superworth

PERRIGO price to free cash flow PRGO

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026
18.6×
10-year median
16.6×
Against its 10-year history
61st
percentile: 0 is its lowest day, 100 its highest
10-year range
6.4× to 53.4×
Peer median
9.6×

PERRIGO's price to free cash flow is 18.6× as of Oct 23, 2026.

That is above its ten-year median of 16.6×, close to the middle of its last ten years.

Over that time it ranged from 6.4× in Nov 2025 to 53.4× in Aug 2022.

The median for 10 large drugmakers of a similar size is 9.6×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.6×7.0×19.3×
20257.0×6.4×23.3×
202423.0×11.7×25.7×
202315.5×13.7×33.4×
202231.4×24.4×53.4×
202126.6×11.6×29.6×
202013.2×10.9×28.9×
201919.8×10.9×20.9×
201810.3×9.6×19.6×
201716.4×12.4×16.4×
201615.6×14.3×23.7×
201521.3×20.8×27.0×

Against its peers

Companies in Drug Manufacturers - General nearest PERRIGO's size, closest first, today.

CompanyPrice to free cash flow
PRGOPERRIGO18.6×
PBHPrestige Consumer Healthcare9.6×
HRMYHarmony Biosciencesn/m
NRIXNurix Therapeutics7.5×
ANIPANI Pharmaceuticals9.6×
PAHCPhibro Animal Health160×
ANABAnaptysbion/m
PCRXPacira BioSciences8.1×
OGNOrganon6.4×
LQDALiquidia25.3×
ARQTArcutis Biotherapeutics100×
Peer median9.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on PERRIGO

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.